6-K filed Aug 10, 2026 at 16:31 ET
Alcon reported Q2 2026 net sales of $2.8 billion, up 8% YoY (7% constant currency), driven by strong performance across Surgical and Vision Care segments. However, reported operating income collapsed to $11 million (from $247 million) and diluted EPS was $0.00 due to a $505 million non-cash impairment charge from discontinuing the PowerVision IOL programs. Core diluted EPS (non-IFRS) rose 11% to $0.84, and the company raised its full-year guidance for core operating margin and core diluted EPS growth, signaling underlying operational strength despite the one-time charge. The market should focus on the core results and raised guidance, which are positive, while the impairment is a non-cash item that does not affect cash flow or long-term objectives.